TacticScaleWhat Cytokinetics Does & How It Makes Money (CYTK)
Updated October 2026 · reflects Cytokinetics's latest reported financials
Biotech developing and selling muscle-targeting drugs for heart disease. The company earns revenue from selling its approved drug MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy in the US.
How Cytokinetics makes money
The company earns revenue from selling its approved drug MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy in the US. It reinvests in clinical development of its pipeline, hoping to win further approvals and add new product sales.
What Cytokinetics does
Cytokinetics is a South San Francisco-based biopharmaceutical company, founded in 1997, that focuses on muscle biology. It designs oral, small-molecule drugs that either activate or inhibit muscle function to treat debilitating diseases, with a strong focus on the heart. Its commercial product, MYQORZO, is a cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The pipeline extends this approach. Aficamten is being developed for hypertrophic cardiomyopathy (HCM), and omecamtiv mecarbil is aimed at heart failure with severely reduced ejection fraction. Earlier-stage assets include ulacamten, a selective cardiac myosin inhibitor in Phase 1 for heart failure with preserved ejection fraction, and CK-089, a fast skeletal muscle troponin activator also in Phase 1. The company's prospects depend on MYQORZO sales and whether these programs succeed in the clinic.
Products & services
- MYQORZO
- Aficamten
- Omecamtiv mecarbil
- Ulacamten
- CK-089
What is Cytokinetics worth?
On an owner-earnings DCF, Cytokinetics's most-likely value is about $16 versus a recent price near $63 (75% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$2) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Corcept Therapeutics (CORT) · Halozyme Therapeutics (HALO) · Exelixis (EXEL)